Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

City attorneys allege major Pharmacy Benefit Managers (PBMs) and insulin manufacturers are conspiring to artificially inflate ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...